Biologically active derivatives of N6-benzyladenosine-5´-monophosphate

Introduction: 
Cytokinin ribosides are phytohormones with anticancer activities against a range of cancer cell lines including leukemia stem cells. Their activity was confirmed in several xenograft models.
Technology description: 
The present invention relates to the use of a compound of formula (I) for treatment of patients suffering from cancers or other proliferative disorders. Cytokinin ribosides, N6-substituted derivatives of adenosin, have only a limited water solubility which complicates preparation of pharmaceutically acceptable formulations. Introduction of 5´-phosphate moiety increases polarity and allows much higher solubility. Parent compound is released by the activity of serum/tissues esterases.
Development status: 
Laboratory scale, data on cell lines, limited ADME/Tox data.
Advantages: 
The invention provides a novel class of cytokinin prodrugs with improved solubility profile.
Commercial offer: 
Exclusive/non-exclusive license to the patent, related know-how and data.
Papers: 
McDermott S. P., Eppert, K., Notta, F., Isaac, M., Datti, A., Al-Awar, R., Wrana, J., Minden, M. D., Dick, J. E. A small molecule screening strategy with validation on human leukemia stem cells uncovers the therapeutic efficacy of kinetin riboside. Blood. 2012 Feb 2;119(5):1200-7. doi: 10.1182/blood-2011-01-330019. Epub 2011 Dec 9. PubMed PMID: 22160482. Voller, J., Zatloukal, M., Lenobel, R., Dolezal, K., Beres, T., Krystof, V., Spíchal, L., Niemann, P., Dzubak, P., Hajduch, M., Strnad, M. Anticancer activity of natural cytokinins: a structure-activity relationship study. Phytochemistry. 2010 Aug;71(11-12):1350-9. doi: 10.1016/j.phytochem.2010.04.018. Epub 2010 Jun 1. PubMed PMID: 20553699.
IP protection: 
CZ 303327 EP 2 563 801 US 2013/0040908 ZA 2012/07173
Technology/IP owners: 
BioApex, s.r.o., Olomouc Institute of Molecular and Translational Medicine, Faculty of Science, Palacky University, Olomouc
Contact: 
More information is available upon signing a CDA/NDA. Please contact IMTM´s director (director@imtm.upol.cz) or the technology transfer office (tto@imtm.upol.cz).